Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2004

View Archived Issues

ATN-161 inhibits tumor progression and bone metastases in a breast cancer model

Canvaxin reported to improve survival of patients with early stage melanoma

Immunotherapy with antigen presenting cells for metastatic breast and prostate cancer

PT-100 increases the antitumor effects of chemotherapy in mice

Combination chemotherapy in a single liposome

Targeting VEGF-A against angiogenesis and lymphangiogenesis

rhIGFBP-3 effective in Herceptin-resistant breast tumors

LEraf-AON inhibits tumor growth in animal models of prostate cancer

AMD-3100 enters fifth phase II trial for stem cell transplantation

Solvay and Wyeth sign bifeprunox development and marketing agreement

DOV discusses phase III plans for bicifadine with FDA

Enrollment under way in phase I trial for PBI-1402

Promising initial clinical results for HYB-2055 presented in Orlando

Dual SRC/ABL kinase inhibitor BMS-354825 for imatinib-sensitive and -resistant CML

Metabasis presents data on liver targeting of adefovir prodrug, Hepavir B

PARP inhibitor KCL-010440 effective against postischemic neural damage in vivo

alpha2delta Ligands and their use in epilepsy, pain, etc.

Novel prenyl transferase inhibitors under study at PPD Discovery

Lion presents new NR3B1 ligands and their therapeutic use

CV Therapeutics claims adenosine A1 agonists with antiarrhythmic and antilipolytic activity

Novel ALK5 inhibitors prepared and tested by GSK team

Dual 5-HT reuptake inhibitors/alpha2-AR antagonists designed at Janssen

Livial evaluated for sexual dysfunction

FDA agreement on protocol for phase III Altropane study

Second safety review completed for endocarditis and bacteremia Cubicin trial

P&G to develop Genzyme's RDP-58 for IBD

Roche and ArQule form partnership in oncology

Genaissance and Lark Technologies close merger

First phase III trial of CDP-870 in rheumatoid arthritis meets primary endpoint

Vioxx approved for acute treatment of migraine

Enrollment commences in pivotal studies of doripenem for cIAI

Ketek receives FDA approval

Orphan drug status for microplasmin in pediatric eye surgery

Imvamune selected as name for Bavarian Nordic's MVA-BN smallpox vaccine